If a tumour cannot be completely removed (R1- or R2-resection) or metastases have formed, our objective is to achieve long-term control over tumour growth and reduce the tumour burden as much as possible by using biological anti-cancer drugs and low-dose chemotherapy. The lower the number of cancer cells, the sooner the immune system can function successfully again. In this way it is quite possible to live with the tumour for a very long time with a good quality of life.
Biological tumour therapy
In line with our holistic approach, the following active substances are used in the form of infusions – either as a stand-alone cytological therapy or in combination with radiation treatment or chemotherapy:
This substance, obtained from apricot kernels, is a cyanogenic glycoside. It is an extremely stable compound whose toxicity only becomes effective when it has been activated by the enzyme ß-glucosidase. It offers selective use against cancer cells because the concentration of ß-glucosidase is about 1,000 times higher in such cells than in normal cells.
The active metabolite cyanide (hydrocyanic acid) is therefore almost exclusively created within cancer cells. At the same time, a cancer cell also contains 30 times less rhodanese, an important detoxification and protective enzyme, than healthy cells. Thus hydrocyanic acid accumulates in cancer cells, triggering their death.
We only use amygdalin as an infusion. Production takes place in a clean-room laboratory (Curafaktur, see above). We expressly do not recommend the oral ingestion of apricot kernels or B17 capsules because this may result in serious side effects in the gastrointestinal tract (increased activation due to ß-glucosidase in the villi of the small intestine).
The intravenous administratio of amygdalin has been classified as harmless by Germany’s Federal Office for Drug Safety. Studies on amygdalin have been taking place for years at Frankfurt University Hospital, where the safety of amygdalin administered intravenously has been confirmed and its effect on tumour cells is being investigated (e.g. Blaheta et al., 2014).
This workgroup has also been able to prove an inhibiting effect on the migration of cancer cells, reducing the formation of metastases. At our clinic we have also observed that when amygdalin is administered regularly the course of the illness has often been very stable – frequently without the formation of any new metastases for years.
The membrane potential of healthy cells is -70 mV, while that of cancer cells is only about -30 mV.
Organic germanium sesquioxide is a strong electron donor, causing repolarisation of the membrane – which cancer cells do not tolerate, and which can trigger their death.
This substance, obtained from the turmeric plant, is the colourant found in curry. It has many very useful properties:
- it inhibits the central cause of inflammation and tumour growth (the NF-kappa-B signalling pathway)
- it triggers programmed cell death (apoptosis) in tumour cells and slows their growth
- it protects healthy cells against the side effects of chemotherapy and radiation treatment
- it stimulates the immune system
- it is a chemosensitizer: curcumin makes cancer cells more sensitive towards the following commonly used chemotherapies:
doxorubicin, 5-FU, taxol/abraxane, vincristine, vinorelbine, gemcitabine, cisplatin, oxaliplatin, etoposide, etc.
- it is a radiosensitizer: curcumin makes cancer cells more sensitive towards radiation therapy
- it enhances the effect of hyperthermia (regional deep hyperthermia, see above)
This substance is obtained from the annual Indian mugwort plant and is effective against all types of cancers (Efferth 2001).
Its selective effect on cancer cells is due to artesunate releasing oxygen radicals – which can damage and destroy the cancer cells – when it chemically reacts with iron.
Cancer cells have higher iron concentrations because they need iron for their multiple cell division. Research work at the German Cancer Research Centre (DKFZ Heidelberg) confirms artesunate’s effectiveness against breast cancer cells (Hamacher-Brady et al., 2011). It also has an inhibiting effect on vessel formation in tumours. This impairs the supply of blood to tumour nodes.
We use artesunate against rapidly growing tumours, in particular.
Vitamin C infusions
High-dose vitamin C infusions: This is not the administration of vitamin C as an anti-oxidant, familiar when one eats fruit and vegetables or food supplements. Clinical studies have shown that vitamin C in very high doses (from 30 grams upwards, intravenously) leads to the formation of cytotoxic amounts of hydrogen peroxide in cancer cells.
Cancer cells have porous cell membranes with a pathologically altered cell membrane voltage, and vitamin C can therefore penetrate cancer cells to a greater extent. Cancer cells have lower amounts of the enzymes catalase and superoxide dismutase. This insufficiency makes them more vulnerable to the lethal effect of the hydrogen peroxide (Kasciari, et al., 2001). The effectiveness of radiation treatment and chemotherapy is therefore enhanced.
Similar effects can be seen in combination with loco-regional deep hyperthermia, which is why we use high-dose vitamin C therapy in parallel to this treatment. Vitamin C also has a strong effect on the immune system, stimulating the TH1 and NK cells that are important for defending against tumours.
It also reduces the side-effects of chemotherapy and radiation treatment, and leads to a tangible improvement in general wellbeing.
An important trace element with a wide range of effects:
- protects healthy cells against the negative effects of chemotherapy and radiation treatment, and should therefore be administered one hour before such therapies.
- converts the protective glutathione in cancer cells to selenodiglutathion, whereby harmful oxygen radicals are created within the cancer cells and their protective glutathione is removed. Selenium thus enhances the effect of chemotherapy and radiation treatments.
- selenium is essential for a functioning immune system
- selenium supports detoxification
The effects of these substances have been investigated in basic research. The pharmaceutical industry has no interest in conducting the large-scale clinical studies that are the prerequisite for general scientific recognition because such natural substances cannot be patented.
We have seen these highly effective herbal substances in clinical everyday use since 2012. Since 2014, we have been producing these substances with maximum quality and under sterile conditions in a modern clean-room laboratory (Curafaktur Heilbronn), where we collaborate with qualified biologists who have been active in leading positions in basic research at the German Cancer Research Centre (DKFZ Heidelberg) for many years.
Insulin potentiation therapy (IPT)
Under continuous observation, the blood sugar of patients is deliberately reduced to the range of moderate hypoglycaemia by means of a precisely calculated dose of insulin. This low level of blood sugar is hardly noticed by patients except for some fatigue and, possibly, light perspiration.
The subsequent chemotherapy mainly affects the cancer cells because cancer cells have about six times as many insulin receptors as healthy ones. After application of the chemotherapy (as a bolus injection or short infusion) it is accelerated into the cancer cells by a glucose infusion and the normal blood sugar level is restored.
With IPT, the dose of chemotherapy can be reduced by about 20% compared to normal, so that there are practically no side effects. This therapy can therefore by carried out in advanced cases and when the patient’s general condition is poor.
Another advantage is that the therapy can be applied once or twice a week over a longer period due to its good tolerance, so long-term control of tumour growth is possible.
Fundamentally, the entire range of chemotherapeutic substances is available. Our chemotherapies are, as usual, prepared by a specialist pharmacy (Rieselfeld Apotheke in Freiburg) and delivered to our clinic.
The choice of chemotherapeutic substances frequently depends on the experiences of classic oncology. We prefer to use combinations proven over decades, particularly at the start of an IPT chemotherapy.
But if resistances do occur, it is possible to isolate circulating tumour cells (CTCs) from the blood using a complicated method (liquid biopsy – Metavectum Hamburg). Then these cancer cells undergo a chemo-sensitivity test specially optimised by Metavectum for the therapies carried out in our clinic.
This test provides information on which therapy is effective, and against which therapies the cancer cells are resistant. In this way we can adapt our therapy precisely, according to the biological properties of the cancer cells found. This process is also called ‘personalised cancer medicine’.
Albumin-carrier therapy with methotrexate (MTX-HSA)
This therapy has several very positive effects on cancer. Firstly methotrexate (MTX), as a chemotherapeutic substance, inhibits the cell division of cancer cells. In addition, methotrexate has an immunomodulatory effect and is strongly anti-inflammatory.
This anti-inflammatory effect has a very important role within an integrative oncological treatment concept becuase inflammatory processes promote the growth of cancer cells.
A central point with MTX-HSA is the bonding of MTX to human serum albumin. Cancer cells have a higher energy requirement than healthy cells, and cover this need through the greater uptake of glucose (see insulin potentiation therapy (IPT) above) and with the increased metabolism of proteins, particularly human serum albumin (HSA).
Albumin can therefore be used as a carrier (like a Trojan horse) for the targeted transport of substances such as methotrexate into cancer cells. In addition, albumin (a protein found in egg white) is very effective against oedemas and ascites (accumulation of water in the peritoneal cavity).
MTX-HSA has a half-life of 19 days so a continuous effective level can be maintained when it is infused every 14 days.
Cancer cells are therefore constantly exposed to therapy that is both anti-inflammatory and also inhibits their cell division (reaching all cell division cycles – unlike when classic chemotherapy is used).
We also refer here to our publication in the journal: Orthomolekulare Medizin und Ernährung [Orthomolecular Medicine and Nutrition] which appeared in July 2018, No. 163, P. F31-F35:
“Die Albumin-Carrier-Therapie mit Methotrexat” [Albumin Carrier Therapy with Methotrexate] (Gaßmann C and Gaßmann E) and on the website of the Albumin Carrier Foundation: www.albumin-carrier-therapie.org